ADMA Biologics, Inc.
ADMA
Updated: 24/09/2026, 06:13:18
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
No summaries found.
- Share price
- $9.70
- Market cap
- $2.25B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Adam S. Grossman
- Employees
- 644
- IPO date
- 17/10/2013
- Beta
- 0.774
- Last dividend
- $0.00
- Day range
- $9.43 – $9.81
- 52-week range
- $7.21 – $20.46
- 1-day performance
- -1.12%
- 1-year performance
- 34.54%
- Current drawdown (1Y)
- -52.59%
- CIK
- 0001368514
- CUSIP
- 000899104
- ISIN
- US0008991046
- Created
- 07/12/2025, 01:56:04
- Last update
- 24/09/2026, 06:13:18
Track ADMA Biologics, Inc. with an AI analyst
See which prediction-market events move ADMA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Newsfile Corp • STOCK • 15/06/2026, 09:45:00
ADMA Shareholder News: ADMA Biologics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law about the Ongoing Securities Class Action
GlobeNewsWire • STOCK • 15/06/2026, 08:33:00
ADMA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Newsfile Corp • STOCK • 14/06/2026, 09:20:00
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
GlobeNewsWire • STOCK • 13/06/2026, 10:01:00
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA
GuruFocus • STOCK • 13/06/2026, 01:00:00
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA
PRNewsWire • STOCK • 13/06/2026, 00:00:00
ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Business Wire • STOCK • 12/06/2026, 22:15:00
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action
Business Wire • STOCK • 12/06/2026, 15:15:00
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA
Newsfile Corp • STOCK • 12/06/2026, 14:17:00
Law Offices of Frank R. Cruz Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action
Business Wire • STOCK • 12/06/2026, 14:06:00
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp • STOCK • 12/06/2026, 14:00:00
ADMA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
GlobeNewsWire • STOCK • 12/06/2026, 11:42:00